Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

Share Price is delayed by 15 minutes
Get Live Data
131.20    -0.40 (-0.30%)
Bid:
130.80
Ask:
131.20
Spread: 0.40 (0.306%)
Market Cap: £319.36m
PRTC Live PriceLast checked at - London Stock Exchange

Intraday PureTech Share Chart

Holding(s) in Company

8 May 2026 07:00

RNS Number : 5074D
PureTech Health PLC
08 May 2026
 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BY2Z0H74

Issuer Name

PURETECH HEALTH PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

Briarwood Chase Management LLC

City of registered office (if applicable)

New York

Country of registered office (if applicable)

USA

4. Details of the shareholder

Name

City of registered office

Country of registered office

Morgan Stanley & Co., LLC

New York

USA

5. Date on which the threshold was crossed or reached

06-May-2026

6. Date on which Issuer notified

07-May-2026

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

5.093400

0.000000

5.093400

12398267

Position of previous notification (if applicable)

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB00BY2Z0H74

12398267

5.093400

Sub Total 8.A

12398267

5.093400%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

 

Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

 

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Aalap Mahadevia

5.093400

5.093400%

Briarwood Chase Management LLC

5.093400

5.093400%

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

 

12. Date of Completion

07-May-2026

13. Place Of Completion

New York, NY USA

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLARMBTMTBMTLF
Date   Source Headline
9th Jun 20227:00 amRNSTransaction in Own Shares
8th Jun 20227:00 amRNSTransaction in Own Shares
7th Jun 20227:00 amRNSTransaction in Own Shares
6th Jun 20225:00 pmRNSTransaction in Own Shares
6th Jun 20227:05 amRNSAkili Adds Another Life Sciences Vet to C-Suite
6th Jun 20227:00 amRNSGLS Data at ADA: Metabolic Benefits & Gut Bacteria
1st Jun 202212:00 pmRNSPRTC to Present at Jefferies Healthcare Conference
1st Jun 20227:00 amRNSTotal Voting Rights
1st Jun 20227:00 amRNSTransaction in Own Shares
31st May 20227:00 amRNSTransaction in Own Shares
30th May 20227:00 amRNSTransaction in Own Shares
27th May 20227:00 amRNSTransaction in Own Shares
26th May 202212:05 pmRNSAkili & Roblox (NYSE:RBLX) Partner on EndeavorRx
26th May 20227:00 amRNSTransaction in Own Shares
25th May 20227:00 amRNSTransaction in Own Shares
24th May 20228:05 amRNSPRTC's Vedanta Presents Data at DDW Annual Meeting
24th May 20227:00 amRNSTransaction in Own Shares
23rd May 20227:00 amRNSTransaction in Own Shares
20th May 20227:00 amRNSTransaction in Own Shares
19th May 20227:00 amRNSPDMR Notification RSU Vesting
19th May 20227:00 amRNSTransaction in Own Shares
18th May 20227:00 amRNSTransaction in Own Shares
17th May 202212:00 pmRNSPRTC to Present at UBS Healthcare Conference
17th May 20227:00 amRNSTransaction in Own Shares
16th May 20222:30 pmRNSPRTC Presents LYT-100 Data at ATS Conference
16th May 20227:00 amRNSTransaction in Own Shares
13th May 20227:00 amRNSTransaction in Own Shares
12th May 20227:00 amRNSTransaction in Own Shares
11th May 20227:00 amRNSTransaction in Own Shares
10th May 20227:00 amRNSTransaction in Own Shares
9th May 20227:00 amRNSPRTC Share Buyback Programme Commences Purchases
5th May 20227:00 amRNSPRTC Announces Share Buyback Programme Up to $50M
4th May 202211:35 amRNSGelesis Presents GS200 Weight Loss Data at ECO
3rd May 20227:00 amRNSTotal Voting Rights
29th Apr 202211:05 amRNSGelesis Data: Therapeutic Shows Gut Health Benefit
26th Apr 20227:00 amRNSPRTC Final Results & Publication of Annual Report
13th Apr 20224:44 pmRNSPRTC's Vedanta Publishes VE303 Data
12th Apr 202212:05 pmRNSAkili Depression Data Published in AJP
12th Apr 20227:00 amRNSGlyph: 20x Oral Bioavailability of Buprenorphine
7th Apr 20227:00 amRNSNotice of Results
1st Apr 20227:00 amRNSTotal Voting Rights
24th Mar 20227:00 amRNSPRTC Appoints Merck Vet to BOD & Audit Committee
17th Mar 20221:05 pmRNSAkili Adds Gaming Vet as Chief Product Officer
16th Mar 202210:35 amRNSGelesis: Record-Breaking Plenity Prescriptions
8th Mar 202212:05 pmRNSAkili Named to World's Most Innovative Companies
18th Feb 20224:30 pmRNSHolding(s) in Company
17th Feb 202212:05 pmRNSAkili Data: Enhanced Brain Activity in Kids w/ADHD
15th Feb 20227:00 amRNSPRTC's Akili Files Registration Statement on S-4
10th Feb 202212:00 pmRNSPRTC to Present at Leerink Healthcare Conference
4th Feb 20227:00 amRNSPDMR DEALING - PURCHASE OF SHARES

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.